Company: PRME
Filing Date: 2025-11-07
Form Type: 10-Q
Source: 0001628280-25-050422
Chunk: 29

Company: Prime Medicine, Inc.
Filing Date: 2025-11-07
Form: 10-Q
Item: Part I, Item 1
Chunk 29
---
 in the Company’s research and development programs. The measure of segment assets is reported on the consolidated balance sheets as total assets.The following table contains additional information on our consolidated net loss, including significant segment expenses:Three Months Ended September 30,Nine Months Ended September 30,(in thousands)2025202420252024Total revenue$1,225 $209 $3,794 $800 Operating expenses:Research and development expensesPersonnel expenses10,898 14,935 40,146 46,140 Facility related11,353 7,735 36,087 26,371 Research costs8,379 9,714 27,531 32,723 General and administrative expenses:Personnel expenses4,370 7,433 18,608 20,273 Other segment items (1)20,198 14,624 41,164 33,538 Total operating expenses55,198 54,441 163,536 159,045 Total other income, net3,391 1,714 4,679 4,639 Net loss$(50,582)$(52,518)$(155,063)$(153,606)(1) Other segment items consist of professional and consultant fees, license and intellectual property fees, general and administrative facility costs, and settlement costs.Recently Issued Accounting Pronouncements Not Yet AdoptedIn December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires enhanced income tax disclosures, including specific categories and disaggregation of information in the effective tax rate reconciliation, disaggregated information related to income taxes paid, income or loss from continuing operations before income tax expense or benefit, and income tax expense or benefit from continuing operations. This guidance is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently in the process of evaluating the impact of this pronouncement on its related disclosures.In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses, which requires more detailed information about specified categories of expenses included in certain expense captions presented on the face of the income statement. This ASU is effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is